Semax Peptide Mitigates Sympathetic Overactivity After Heart Attack in Rats
Background
The sympathetic nervous system plays a crucial role in regulating cardiovascular function, but its excessive activation significantly aggravates the course of myocardial infarction (MI), commonly known as a heart attack. This overactivity can lead to detrimental remodeling and worsened outcomes. This study aimed to investigate whether the neuroprotective peptide Semax could moderate this sympathetic activation and prevent associated changes in vascular innervation and adrenoreceptor density following experimental MI.
Results
The study revealed that Semax peptide effectively moderated the degree of sympathetic nervous system activation in rats post-MI. It specifically prevented the increase in the density of sympathetic nerve endings in the rat caudal artery observed 28 days after either ischemia or ischemia/reperfusion injury, indicating a significant neuroprotective effect on innervation. Semax also reduced the density of α-adrenoreceptors in the caudal artery of rats with myocardial infarction, suggesting a beneficial modulation of adrenergic signaling pathways. Importantly, the peptide produced no effect on β-adrenoreceptors in both experimental models, highlighting a selective action. Experiments on isolated segments of the caudal artery further demonstrated that Semax-treated rats exhibited reduced vascular responsiveness to both electrical stimulation and norepinephrine infusion after ischemia/reperfusion injury, indicating improved vascular function.
Why It Matters
Sympathetic overactivity is a well-established driver of adverse cardiac events and poor prognosis following myocardial infarction. The findings that Semax peptide can moderate this activation, prevent sympathetic nerve proliferation, and reduce α-adrenoreceptor density are highly significant. This positions Semax as a potential novel therapeutic agent for mitigating the detrimental effects of sympathetic nervous system activation and improving cardiovascular recovery post-MI. Further preclinical studies are needed to establish optimal dosing and long-term effects, paving the way for potential human clinical trials.